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Nicotine can stimulate both sympathetic and parasympathetic ganglionic cells depending 
on which ganglionic cells of the ANS it is able to access. This study involved the transdermal 
delivery of low doses of nicotine and nitroglycerin to the forehead and finger microvasculature so 
as to test the hypothesis that, although both drugs will cause vasodilation at the forehead, the 
nature of the dilation will differ as a consequence of their different sites of action within the 
neuro-microvascular pathways.  With IRB approval, the local effects of transdermal nitroglycerin 
and nicotine were investigated on the forehead and finger of 10 healthy volunteers resting supine 
in a temperature-regulated room (22±1°C).  Each micropatch was placed on the forehead and 
finger beneath a laser Doppler flowmetry (LDF) probe which measured the relative blood flow.   
The changes in the height (AC) and the baseline (DC) components of the laser Doppler signal 
were assessed as well as the power of the signal at different frequencies.  Both drugs caused 
significant vasodilation at the forehead vasculature. The increase in the AC component was larger 
for nicotine than for nitroglycerin. Similarly the DC component showed a larger increase for 
nicotine than for nitroglycerin. There was no significant increase in either component at the 
finger. The FFT analysis showed marked oscillatory activity at the nicotine application site for 
virtually every frequency that we studied up to about 0.3. Both nicotine and nitroglycerin caused 
vasodilation of the forehead microvasculature while not at the finger.  Nicotine may turn out to be 
the ideal transdermal preparation for testing a disorder such as diabetic neuropathy and the impact 
of diabetes on endothelium-dependent vasodilation.  Since intact postganglionic parasympathetic 
fibers are required for nicotine to exert its vasodilatory effect on the microvasculature, application 
of a nicotine micropatch not only would test the vessel but also the post-ganglionic pathway and, 
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Nicotine is a drug consumed by millions of people worldwide. It is the main 
compound responsible for addiction to tobacco. Nicotine replacement therapy in the form 
of gum, transdermal patches, inhalers and nasal sprays is also widely used and is a 
strategy employed for smoking cessation.  It is a very intriguing drug from a physiologic 
standpoint. The majority of data related to nicotine is focused on the systemic effects of a 
relatively large dose of nicotine administered intravenously or locally and on its role as a 
smoking cessation tool.  
The effects of transdermal nicotine on the local microvasculature are not well 
studied. However, as technology has improved, tools such as laser doppler flowmetry 
(LDF) have emerged for measuring local blood flow. In this study, we investigated the 
effects of transdermal nicotine on the skin microvasculature at different sites. We then 
compared this response to nitroglycerin (a known vasodilator) in order to assess whether 
there were differences in the response given the different mechanisms of action for each 
drug.  
It is well established that nicotine can stimulate sympathetic ganglionic cells in 
low and moderate concentrations and thereby causes vasoconstriction and increased heart 
rate among other effects [1]. It can also paralyze these cells at high doses. Less 
appreciated is the fact that nicotine can also stimulate parasympathetic ganglionic cells 





dependent on which ganglionic cells it is able to gain access to and which branch of the 
autonomic nervous system is dominant in that region.  
As previously mentioned, nicotine (NIC) is a neurotransmitter that can activate 
both sympathetic and parasympathetic pathways. It is released by pre-ganglionic neurons 
of both systems resulting in the release of norepinephrine (by postganglionic sympathetic 
fibers) and acetylcholine (by postganglionic parasympathetic fibers).   
Acetylcholine (ACh) is a known vasodilator. It is an endothelium dependent 
vasodilator [2] which means that it requires intact endothelial cells to produce 
vasodilation. This is because ACh, acting on ACh receptors on these cells, stimulates 
release of the substances that cause vasodilation of the smooth muscle cells. Using 
invasive measurements, it has been shown that the vasodilatory effect of acetylcholine is 
impaired in patients with coronary artery disease [3]. Since ACh requires intact 
endothelial cells in to function, ACh can be used to assess endothelial function. 
 A previous study by Schonberger et al [4] has used LDF to compare the response 
of a prepared ACh transdermal patch with commercially available nitroglycerin 
transdemal patch. They found an increase in blood flow in response to the application of 
these patches. They were limited in that there is no commercially available acetylcholine 
patch and hence had to produce their own. However, this was the first study of its kind 
using LDF in conjunction with a translucent drug patch to measure changes in blood 
flow. Since no ACh patch is available, transdermal nicotine is a good alternative in that it 
stimulates ACh release via the mechanisms described above. Moreover, a commercially 





 Using these patches with different mechanisms of action may provide insight into 
the mechanism of blood flow regulation in tissues rich in cholinergic innervations (e.g. 
centrally located regions) but not in tissues where such innervation is sparse or lacking 
(e.g., more peripheral regions). 
Systemic nicotine affects the cardiovascular system and typically leads to direct 
and indirect increases in heart rate, blood pressure and also causes vasoconstriction. This 
is due to its sympathomimetic effects as it stimulates the release of catecholamines. These 
increases in heart rate and blood pressure increase myocardial work and oxygen demand. 
Moreover, coronary vasoconstriction can lead to a decrease in blood flow to the heart.  
These effects of nicotine can lead to significant morbidity and mortality especially in 
individuals with underlying coronary artery disease. Given its mechanism of action, 
application of transdermal nicotine to the forehead activates parasympathetic pathways 
and thereby causes vasodilation of the local microvasculature.  This may provide insight 
into the mechanism of blood flow regulation in tissues rich in cholinergic innervations 
(e.g., centrally located regions) but not in tissues where such innervation is sparse or 
lacking (e.g., more peripheral regions). 
When administered systemically, nicotine can gain access to pre-/post- ganglionic 
junctions of both divisions of the autonomic nervous system.  However, if given in a 
small dose via the transdermal route, it should have no effect on the sympathetic 
junctions since the synapse occurs in the paraverterbral sympathetic chain.  Alternatively, 
it may have an effect on parasympathetic junctions: in tissues which are innervated by the 
parasympathetic nervous system, the pre/post synapse occurs near the end organ (e.g., 





 Transdermal nicotine patches deliver on average between 15-22mg of nicotine per 
day depending on the type of patch used and whether it is used during sleep. [1] The 
nicotine is slowly absorbed and blood plasma levels rise gradually over the course of 6-
10 hours, then stay at steady state for 7-8 hrs eventually declining during the last 6 hours. 
The amount absorbed into the blood stream varies by individual and is determined by 
several factors including nicotine clearance, cutaneous blood flow, skin temperature etc.  
The half life of nicotine is about 2-3 hours and it is metabolized by the liver, and to a 
lesser extent in the lung and brain. Studies have shown the 21mg transdermal nicotine is 
safe [5]. In this study, transdermal nicotine patches were left in place for 30 minutes 
minimizing systemic effects substantially. In addition, the patches used were markedly 
smaller than the original patch and only measured about 2cm X1cm.  
 
NITROGLYCERIN 
Nitroglycerin is a drug used to relieve the symptoms of angina. It has generally 
been assumed that nitroglycerin relieves symptoms via the release of nitric oxide (NO), 
which relaxes vascular smooth muscle cells. This occurs independently of acetylcholine 
and other means of releasing NO (since the NO is supplied by the nitroglycerin). 
In light of the different mechanisms of action of nicotine and nitroglycerin, we set 
out to measure and quantify the response to local transdermal doses of nicotine and 
nitroglycerin in different body regions. This will be accomplished by measuring the 





the autonomic response by measuring the frequencies of the response. This is due to the 





LASER DOPPLER FLOWMETRY 
Laser doppler flowmetry (LDF) is a non invasive method that has many practical 
applications which include the measurement of microvascular blood flow. This allows us 
to monitor blood flow changes to the tissue and thus can be a useful tool to assess the 
effects of drugs on the tissue. While LDF does not provide absolute values, it gives us a 
means of measuring relative changes. Hence, once a baseline flow is established, relative 
increases or decreases in flow can be determined and quantified.  Measuring skin 
perfusion has many clinical applications as many diseases can affect the skin such as 
diabetic microangiopathy, Raynaud’s phenomenon, peripheral vascular disease leading to 
various complications such as ulcers, neuropathies etc. In addition, it has clinical 
applications in plastic surgery especially in flap surveillance, burns and pharmacology. 
Hence, as a clinical tool, LDF allows the monitoring of skin blood perfusion in 
real time, continuously and non invasively.  The theory behind LDF, as its name implies, 
is based on the Doppler effect which was described by Johan Christian Doppler . LDF are 





receiving fibers allowing for a sampling depth of approximately 1mm for human skin.  
Coherent light directed towards the tissue causes photons to be scattered by both moving 
and static objects. In the case of a moving object, the doppler effect occurs causing a 
change in photon frequency. The reemitted light is then directed towards a photodetector 
in which the combination of the shifted and non shifted light frequencies give rise to a 
stochastic photocurrent. The properties of this photocurrent is related to the properties of 
the blood cells present in the illuminated volume as they move at their different 
velocities. Light can be viewed as a particle with some wave characteristics.  The doppler 
effect results in the scattering of light due to its interactions with the red blood cells.  
These red blood cells are moving at very low velocities (mm/s) and hence give 
rise to extremely small frequency shifts, much smaller than that of the incident light. 
Several mathematical equations and models are thus used to give an estimate of the blood 
flow. Several models have been proposed using complex mathematical equations. In 
other for these models to work, certain assumptions need to be made. These assumptions 
may not be fully true in biologic tissue but give us a good framework in which to make 
these calculations. A few of these assumptions are outlined by Humeau et al [1] and are 
as follows :  
1. Light suffers multiple scattering in the static tissue matrix, hence becoming 
diffusely scattered. 
2. The fraction of photons undergoing multiple doppler shifts is negligible.  
3. The blood cell velocities are randomly distributed in direction within the 





random on a length scale defined by the mean distance between RBC 
scattering events.  
4. The statistics of the blood cell velocity field is uniform throughout the 
scattering volume.  
In summary, LDF measurements have evolved from the intial reports by Riva et 
al in 1972, who reported that microvasculature blood flow measurements could be 
measured with the Doppler effect. Several studies have been carried out to improve the 
technique and measurements and the theory has now been established. LDF will only 
continue to grow as a tool for measuring tissue perfusion, a very important indicator of 
















STATEMENT OF PURPOSE 
 
To measure the response of the forehead and finger microvasculature to transdermal 
nicotine and transdermal nitroglycerin using laser doppler flowmetry on healthy 
volunteers.  Since these drugs work by different mechanisms, this can be used as a novel 
non invasive way to assess the function of the microvasculature as we can compare the 
























The study was carried out on 10 healthy non-smoking volunteers between the 
ages of 20 and 26 who were instructed to refrain from caffeine for at least twenty four 
hours.  After informed consent was obtained, the subjects lay on a bed in a semi-
recumbent position in a temperature controlled room (22+1C) and were monitored using 
an ECG and non-invasive brachial artery blood pressure cuff. A baseline blood pressure 
and pulse were obtained at the beginning of the experiment in other to monitor any 
systemic changes. 
   A 6-mm diameter circle was obtained from the two patches: a clear nitroglycerin 
patch (Minitran, 3M Pharmaceuticals, Northridge, CA) and transdermal nicotine 
(Nicoderm CQ, GlaxoSmithKline). Each subject received both the nicotine and 
nitroglycerin patch in separate sessions. The order was randomly determined.    
 Each micropatch (i.e the nicotine or nitroglycerin patch) was placed on the 
forehead beneath a laser Doppler flowmetry (LDF) probe (PF5010, Perimed),   a second 
LDF probe was placed on the finger, while the third LDF probe served as the control for 
the forehead.  There was no finger control since there were only three probes available.   
LDF readings were recorded continuously at 200 Hz for 20 minutes, with a data 
acquisition system (PowerLab, ADInstruments) and analyzed with commercially 






The changes in the height (AC) and the baseline (DC) components of the laser 
Doppler signal were assessed for each drug and compared with placebo using a paired t 
test.  
Microvascular oscillatory patterns were delineated with spectral analysis for each LDF 
tracing using a 32K FFT size and a Hamming window. Three different frequency ranges 
(0.05-0.11, 0.12-0.19 and 0.2-0.3 were selected and analyzed for each site. The basis for 
these three bands is addressed below.  The low frequency bands (0.05- 0.11Hz) represent 
oscillations in the microvasculature due to sympathetic activity. These sympathetic-
induced oscillations are limited to low frequencies (<9 cycles/s) [6].  The oscillations 
occurring at higher frequency bands ( > 9 cycles/s)  represent parasympathetic mediated 
activity. The cholinergic etiology of these HF oscillations was confirmed by their 
elimination by systemic administration of atropine. [7]. The higher frequency band (0.12-
0.3 Hz) was divided into an intermediate frequency band (0.12-0.19Hz) and a high 
frequency band (0.2-0.3Hz).  This is in order to distinguish between oscillations 
transmitted to microvasculature due to respiration (which typically  has a frequency of 
~0.2Hz) or a cholinergic mediated process occurring at the level of the 
microvasculature.[6]   
 
The presence of systemic effects was monitored at the control site, as well as by 









TIME DOMAIN RESULTS 
 
Figure 1a- Nicotine Laser Doppler Tracings showing forehead, placebo and finger 
as drug from patch is absorbed over time. 
 
 
Figure 1a shows a tracing from a single subject. Channel 1 (uppermost channel) shows 
the LDF tracing for nicotine at the forehead. Channel 2 (middle channel) shows the 
placebo at the forehead. Channel 3 (bottom channel) shows the tracing for nicotine at the 
finger site.  The forehead tracing shows an upward change as time progresses. The 
placebo tracing remains unchanged while the finger tracing shows large fluctuations but 












Figure 1b- Nicotine Laser Doppler Tracings magnified 
 
 
Figure 1b above shows a magnified portion of the Figure 1a.  This illustrates that the 
tracing is composed of individual oscillating waveforms.  The forehead tracing shows an 
increase in the LDF signal accompanied by an increase in the height of the individual 
waveforms. The placebo tracing shows no increase in LDF signal value and the 
individual waveforms remain unchanged.  The finger tracing shows a minimal increase in 











Figure 2a- Nitroglycerin Laser Doppler Tracings of forehead, placebo and finger in response to 
drug from patch being absorbed over time. 
 
Figure 2a shows a tracing from a single subject. Channel 1 (uppermost channel) shows the LDF 
tracing for nitroglycerin at the forehead. Channel 2 (middle channel) shows the placebo at the 
forehead. Channel 3 (bottom channel) shows the tracing for nitroglycerin at the finger site.  The 
forehead tracing shows an upward change as time progresses. The placebo tracing remains 














Figure 2b- Nitroglycerin Laser Doppler Tracings Magnified 
 
Figure 2b above shows a magnified portion of the Figure 2a.  This illustrates that the tracing is 
also composed of oscillations which change over time as nitroglycerin is absorbed.  The 
forehead tracing shows an increase in the LDF signal accompanied by an increase in the 
individual waveforms. The placebo tracing shows no change in LDF value and the individual 






























BASELINE POST  
1 0.2048 0.157 0.1625 0.4727 
2 0.1108 0.09523 0.06363 0.3985 
3 0.1106 0.1007 0.07804 0.4955 
4 0.05285 0.079915 0.1124 0.369 
5 0.5156 0.6549 0.062565 0.1807 
6 0.13355 0.1103 0.04961 0.1921 
       7 0.067565 0.067315 0.07411 0.1115 
8 0.01739 0.02531 0.02633 0.03677 
9 0.048315 0.04924 0.04824 0.13385 
10 0.0375 0.037735 0.0692 0.361 
     MEAN 0.129897 0.1377645 0.0746625 0.275162 
SD 0.146363266 0.185752101 0.038167714 0.162741626 
median 0.0890825 0.0875725 0.066415 0.27655 
min  0.01739 0.02531 0.02633 0.03677 
max 0.5156 0.6549 0.1625 0.4955 
*BaselinePRE – defined as the trough of the waveform before drug administered                 
* BaselinePOST- trough value after drug administered.  
 
 
TABLE 2- T TEST PROCEDURE NICOTINE FOREHEAD BASELINE 
Difference = FOREHEAD NICOTINE BASELINERATIO – FOREHEAD NICOTINE BASELINE 
RATIO 
N MEAN STD DEV STD ERR MIN MAX 
10 2.5835 1.9069 0.6030 -.0589 5.4388 
      
  DF T value Pr> |t|  










Table 1 above compares the changes in Forehead Baseline values pre and post drug 
administration for nicotine compared to placebo. Baseline is defined as the trough of the 
waveform. At the forehead, transdermal nicotine patch resulted in a significant increase in the 
baseline value with an increase in the mean from 0.07 to 0.27 while the mean remained 
unchanged for placebo.  The t test in table 2 showed these results to be statistically significant 
with a p value of 0.002.  
 














1 0.01495 0.021715 0.03086 0.1535 
2 0.05835 0.05038 0.02308 0.1686 
3 0.057995 0.05079 0.028125 0.14465 
4 0.013885 0.02759 0.02661 0.05571 
5 0.1237 0.1601 0.050205 0.1053 
6 0.06601 0.06124 0.022295 0.06311 
7 0.018085 0.01561 0.0205 0.03399 
8 0.015715 0.003125 0.015305 0.01565 
9 0.01996 0.02012 0.02063 0.05092 
10 0.007589 0.0048435 0.01952 0.099155 
     MEAN 0.0396239 0.04155135 0.025713 0.0890585 
SD 0.036777011 0.046127155 0.009725564 0.053330247 
median 0.0190225 0.0246525 0.0226875 0.0811325 
min  0.007589 0.003125 0.015305 0.01565 













Table 3 above compares the changes in Forehead Height values pre and post drug 
administration for nicotine compared to placebo. Height is defined as the peak of the 
waveform. At the forehead, transdermal nicotine patch resulted in a significant increase 
in the Height value with an increase in the mean from 0.03 to 0.09 while placebo remained 
unchanged from 0.039 to 0.041.  The t test in table 4 showed that these results to be 
statistically significant (See Table 2) with a p value of 0.0048.  
At the forehead, both baseline and height approximately tripled in response to 
transdermal nicotine with baseline increasing approx 3.85 times compared to height 
increasing approx 3 times. 
 
TABLE 4- T TEST PROCEDURE NICOTINE FORHEHEAD HEIGHT 
Difference = FOREHEAD NICOTINE BASELINERATIO – FOREHEAD NICOTINE BASELINE 
RATIO 
N MEAN STD DEV STD ERR MIN MAX 
10 2.45 2.0974 0.6601 0.1065 6.44 
      
  DF T value Pr> |t|  






Table 5- Forehead Nitroglycerin Baseline Values 










1 0.1357 0.2367 0.1094 0.2987 
2 0.048345 0.051735 0.083635 0.1529 
3 0.08125 0.08458 0.09732 0.2102 
4 0.09746 0.1045 0.09796 0.2799 
5 0.12545 0.11535 0.041265 0.08307 
6 0.1187 0.1636 0.06358 0.1134 
7 0.10465 0.09281 0.05311 0.1029 
8 0.1031 0.13 0.1216 0.2981 
9 0.05557 0.07837 0.05513 0.15685 
10 0.07906 0.073775 0.092545 0.1675 
 
    
MEAN 0.0949285 0.113142 0.0815545 0.186352 
SD 0.028838006 0.053681355 0.026823487 0.081464272 
median 0.10028 0.098655 0.08809 0.162175 
min  0.048345 0.051735 0.041265 0.08307 








TABLE 6- T TEST PROCEDURE NITROGLYCERIN FORHEHEAD BASELINE 
Difference = FOREHEAD NITRO BASELINERATIO – FOREHEAD NITRO BASELINE RATIO 
N MEAN STD DEV STD ERR MIN MAX 
10 1.0700 0.3720 0.1176 0.4053 1.7851 
      
  DF T value Pr> |t|  









Table 5 above compares the changes in Forehead Baseline values pre and post drug 
administration for nitroglycerin compared to placebo. Baseline is defined as the trough of the 
waveform. As shown above, transdermal nitro patch resulted in a significant increase in the 
baseline value with an increase in the mean from 0.081 to 0.18 while the mean remained 
unchanged for placebo.  The t test in table 6 showed these results to be statistically significant 
with a p value < 0.0001. 













1 0.03206 0.03869 0.02466 0.05583 
2 0.004375 0.005625 0.02092 0.04572 
3 0.046715 0.047415 0.04184 0.08282 
4 0.07562 0.07338 0.0298 0.051145 
5 0.03993 0.038935 0.017125 0.02869 
6 0.04471 0.03073 0.02597 0.04026 
7 0.0274 0.0226 0.020515 0.02514 
8 0.0075 0.004063 0.024745 0.06122 
9 0.023555 0.01672 0.01655 0.0553 
10 0.38325 0.44855 0.02585 0.046125 
     
MEAN 0.0685115 0.0726708 0.0247975 0.049225 
SD 0.112469849 0.13367253 0.007289561 0.016535355 
median 0.035995 0.03471 0.0247025 0.048635 
min  0.004375 0.004063 0.01655 0.02514 









Table 7 above compares the changes in Height values pre and post drug administration 
for nitroglycerin compared to placebo. Height is defined as the peak of the waveform. 
As shown above, transdermal nicotine patch resulted in a significant increase in the 
Height value with an increase in the mean from 0.024 to 0.049.  The t test in table 8 
showed that these results to be statistically significant (See Table 2) with a p value of 
0.0007. 










1 2.229 1.4035 0.3017 0.3323 
2 0.4115 0.6481 0.1053 0.1975 
3 0.5828 0.5911 1.8585 2.931 
4 0.55305 0.7157 0.6933 1.4985 
5 0.7278 0.7576 1.916 1.8095 
6 1.375 1.302 0.225 0.3595 
7 1.461 1.846 0.7785 1.391 
8 0.01541 1.5025 0.11305 0.8521 
9 0.4083 0.50215 0.9962 0.84865 
10 0.3719 0.6518 1.353 1.7375 
     
MEAN 0.813576 0.992045 0.834055 1.195755 
SD 0.66869102 0.473910518 0.686688323 0.849247482 
median 0.567925 0.73665 0.7359 1.12155 
min  0.01541 0.50215 0.1053 0.1975 
max 2.229 1.846 1.916 2.931 
 
TABLE 8- T TEST PROCEDURE NITROGLYCERIN FORHEHEAD HEIGHT 
Difference = FOREHEAD NITRO HEIGHT RATIO – FOREHEAD NITRO HEIGHT RATIO 
N MEAN STD DEV STD ERR MIN MAX 
10 1.0809 0.6800 0.2150 0.4006 2.6316 
      
  DF T value Pr> |t|  






At the finger, neither transdermal nicotine or nitroglycerin produced a statistically 
significant increase in the mean baseline value (Table 9).  However, for nitroglycerin, all 
but 2 subjects showed an increase in baseline values.  The t test (table 10) showed that 
there was no difference between nicotine and nitroglycerin at the finger. 
 












1 0.4114 0.4029 0.15 0.1076 
2 0.08622 0.09903 0.05793 0.1014 
3 0.05805 0.06543 0.08577 0.11755 
4 0.09755 0.1032 0.086535 0.18525 
5 0.035665 0.02949 0.1441 0.2847 
6 0.3898 0.4143 0.06231 0.1082 
7 0.4243 0.4425 0.2642 0.2734 
8 0.015825 0.3066 0.018315 0.3276 
9 0.07122 0.2133 0.2469 0.21495 
10 0.06453 0.09367 0.38325 0.44855 
     
MEAN 0.165456 0.217042 0.149931 0.21692 
SD 0.169491441 0.160758375 0.114761702 0.116277291 
median 0.07872 0.15825 0.1153175 0.2001 
min  0.015825 0.02949 0.018315 0.1014 
max 0.4243 0.4425 0.38325 0.44855 
 
 
TABLE 10- T TEST FINGER NITROGLYCERIN VS NICOTINE BASELINE 
Difference = FINGER NICOTINE BASELINE RATIO – FINGER  NITROGLYCERIN 
BASELINE RATIO 
N MEAN STD DEV STD ERR MIN MAX 
10 -0.18 0.5483 0.1734 -1.0642 0.7480 
      
  DF T value Pr> |t|  






At the finger, neither transdermal nicotine or nitroglycerin produced a statistically 
significant increase in the mean height value (Table 11).  However, for nitroglycerin, all 
but 1 subject showed an increase in height values.  The t test (table 12) showed that there 
was no difference between nicotine and nitroglycerin at the finger. 
FREQUENCY DATA 




























1 5.63166E-06 0.000110025 2.49636E-07 2.97973E-05 3.35998E-06 1.7396E-05 
2 3.72965E-06 3.53911E-05 2.0305E-06 1.70647E-05 3.0235E-06 2.82662E-05 
3 4.45215E-06 0.000174027 3.38021E-06 1.70575E-05 4.68164E-06 1.27978E-05 
4 3.65387E-06 2.30778E-05 1.27075E-06 7.47765E-06 4.60988E-07 3.95348E-06 
5 1.7489E-06 3.20392E-06 1.96322E-06 1.35523E-06 7.83363E-07 2.13073E-06 
6 1.58617E-05 0.000104949 6.3265E-06 4.65265E-05 1.85889E-06 2.96587E-05 
7 8.1573E-06 5.85464E-06 2.26862E-05 8.25939E-06 2.96968E-06 1.10726E-06 
8 7.65652E-07 2.78587E-06 1.01985E-06 1.03477E-06 3.96838E-07 8.78938E-07 
9 6.81623E-06 2.64045E-05 3.52142E-06 7.21656E-06 1.36121E-06 6.61361E-06 
10 7.0996E-06 1.6749E-05 1.29325E-06 6.79217E-06 1.21396E-06 3.85717E-06 
 
      
MEAN 5.79167E-06 5.02467E-05 4.37416E-06 1.42582E-05 2.01101E-06 1.0666E-05 
SD 4.24275E-06 5.86637E-05 6.66292E-06 1.4248E-05 1.43341E-06 1.09958E-05 
median 5.04191E-06 2.47412E-05 1.99686E-06 7.86852E-06 1.61005E-06 5.28355E-06 
min 7.65652E-07 2.78587E-06 2.49636E-07 1.03477E-06 3.96838E-07 8.78938E-07 





TABLE 12- T TEST FINGER NITROGLYCERIN VS NICOTINE HEIGHT 
Difference = FINGER NIC HEIGHT RATIO – FINGER  NITRO HEIGHT RATIO 
N MEAN STD DEV STD ERR MIN MAX 
10 0.0413 1.0658 0.3370 -1.1489 2.1243 
      
  DF T value Pr> |t|  


































1 1.47979E-05 2.55146E-05 1.87651E-06 3.02624E-05 1.45156E-06 3.78071E-06 
2 4.33692E-06 8.86632E-06 5.15565E-06 1.70664E-05 6.46802E-06 9.27677E-06 
3 3.98981E-06 1.58643E-05 4.49222E-06 5.09366E-06 3.16375E-06 4.62797E-06 
4 1.04493E-05 1.74053E-05 2.01758E-05 4.04614E-05 2.84992E-06 4.89007E-06 
5 1.199E-05 2.33307E-05 6.69577E-06 1.44572E-05 9.30115E-06 8.34185E-06 
6 4.02893E-06 2.38241E-06 6.50801E-07 1.68911E-06 4.50839E-07 5.93199E-07 
7 1.19847E-05 1.80827E-06 1.48299E-05 1.41082E-05 3.29327E-06 4.1182E-06 
8 4.35106E-06 1.89279E-06 6.91813E-07 7.08439E-06 3.05284E-07 6.54937E-07 
9 2.79192E-06 6.94711E-06 1.12438E-05 4.3055E-05 1.03984E-06 7.04108E-06 
10 1.55688E-06 5.32697E-06 9.4687E-07 1.69044E-06 1.19139E-06 1.85762E-06 
       MEAN 7.02774E-06 1.09339E-05 6.67591E-06 1.74968E-05 2.9515E-06 4.51824E-06 
SD 4.73495E-06 8.95804E-06 6.70528E-06 1.53711E-05 2.88895E-06 3.01648E-06 
median 4.34399E-06 7.90671E-06 4.82393E-06 1.42827E-05 2.15074E-06 4.37309E-06 
min 1.55688E-06 1.80827E-06 6.50801E-07 1.68911E-06 3.05284E-07 5.93199E-07 


















































1 9.75286E-06 0.000109955 2.05979E-06 2.9737E-05 5.27039E-06 1.7429E-05 
2 4.94911E-05 3.74795E-05 3.16592E-06 1.9876E-05 2.95105E-06 1.9453E-05 
3 0.000107402 0.000167871 1.56064E-05 2.29289E-05 4.69651E-06 4.7293E-06 
4 0.0413554 7.52615E-06 0.017088506 8.77705E-06 0.005713136 1.5021E-06 
5 7.3962E-06 7.52765E-06 1.0757E-06 1.77838E-06 9.84427E-07 1.6627E-06 
6 6.17572E-05 0.000761967 6.16374E-05 9.37107E-05 5.08541E-06 1.3548E-05 
7 5.58782E-06 3.52351E-06 3.79876E-05 3.11302E-05 2.14153E-06 1.9917E-06 
8 0.001285944 0.001096446 0.000105332 0.000285643 2.63514E-05 6.0851E-05 
9 0.000277408 0.002191646 3.86844E-05 0.000415072 1.45515E-05 0.00012599 
10 1.48032E-05 0.000142084 9.32949E-06 1.20237E-05 1.00419E-06 4.2494E-06 
 
      
MEAN 0.004317494 0.000452603 0.001736338 9.20676E-05 0.000577617 2.5141E-05 
SD 0.013019687 0.000714889 0.005394303 0.000141771 0.001804455 3.9681E-05 
median 5.56242E-05 0.000126019 2.6797E-05 2.63329E-05 4.89096E-06 9.1388E-06 
min 5.58782E-06 3.52351E-06 1.0757E-06 1.77838E-06 9.84427E-07 1.5021E-06 
















































1 1.75291E-05 0.000107778 0.000107778 1.15721E-05 1.8499E-05 7.12234E-06 
2 3.19867E-05 0.000327441 4.81822E-06 6.68372E-05 2.55548E-06 1.02487E-05 
3 4.01445E-05 0.000159734 5.03476E-06 4.23115E-05 1.5365E-05 2.76726E-05 
4 1.7061E-05 0.000329429 6.49765E-06 0.000208551 1.59516E-05 4.3457E-05 
5 0.000317087 0.00281988 1.15429E-05 0.000515224 1.83789E-05 5.17014E-05 
6 0.006798816 0.008085137 0.000298998 0.000246301 0.000135497 4.99673E-05 
7 0.004471654 0.012267326 0.000591854 0.001551734 0.000351921 0.000123079 
8 0.001604435 0.00154584 0.000140052 0.000195113 4.68507E-05 3.18929E-05 
9 0.01005842 0.002191646 0.001690569 0.000788539 0.000274101 0.000195189 
10 0.000269287 0.014502756 0.000178567 0.000784759 6.69528E-05 0.00014961 
       
MEAN 0.002362642 0.004233697 0.000303571 0.000441094 9.46073E-05 6.89939E-05 
SD 0.003564035 0.005398995 0.00052063 0.000484648 0.000122786 6.41399E-05 
median 0.000293187 0.001868743 0.000123915 0.000227426 3.26748E-05 4.67122E-05 
min 1.7061E-05 0.000107778 4.81822E-06 1.15721E-05 2.55548E-06 7.12234E-06 
max 0.01005842 0.014502756 0.001690569 0.001551734 0.000351921 0.000195189 
 
The vasodilation associated with each drug was accompanied by increases in each 
frequency band.  
Nonparametric Kruskal-Wallis one-way anova was used to test the difference in 
following variables among three frequency groups (low, intermediate, high).  Unadjusted 
p-values were shown. 
Results: 
Pre Forehead Nicotine,  p= 0.18; Post Forehead Nicotine,  p = 0.054 
Pre Forehead Nitroglycerin, p = 0.25; Post Forehead Nitroglycerin, p = 0.23 
Pre Finger Nicotine, p = 0.23; Post Finger Nicotine, p = 0.04 







The results show no statistical significance for pre measurements among three frequency 
groups. For post- measurements, there was significant difference in post Finger nitro 
among three groups (p = 0.003). There was nominal difference in Post finger nicotine (p 























Both transdermal nicotine and nitroglycerin resulted in vasodilation of the 
forehead microvasculature resulting in a statistically significant increase in blood flow as 
measured by the laser Doppler.  Nicotine resulted in a larger increase in baseline blood 
flow than nitroglycerin (285% (0.07 0.27) vs 122% (0.081  0.18)).  It also resulted in 
a larger increase in height for nicotine 200% (0.03 0.09) vs nitroglycerin 104% (0.024  
0.049). It is not clear whether this effect is dose dependent.  In addition, both drugs caused 
a significant increase in the baseline and height of the waveform when compared with 
placebo.  Nicotine produced a greater increase in both baseline and height of the 
waveform compared with nitroglycerin.  
The vasodilation due to the transdermal nicotine can be explained by nicotine 
stimulating cholinergic activity. While the forehead microvasculature receives dual 
innervation from the parasympathetic and sympathetic nervous systems, transdermal 
nicotine only was able to act upon the ganglionic junctions of the parasympathetic system 
since these synapse near the end organ( i.e the blood vessels).  Since nicotine was not 
able to access the synapses of the sympathetic system located in the thoracolumbar chain 
it did not stimulate the sympathetic nervous system to produce vasoconstriction. Nicotine 





It is possible, but very unlikely that nicotine was able to gain access to the 
nicotinic receptors of the sympathetic system given the low doses used and the short time 
frame < 30 minutes in which to act. It is more likely that feedback mechanisms in place 
to regulate blood flow were activated resulting in the sympathetic system 
counterbalancing the direct activation of the parasympathetic system. 
At the finger, there is no appreciable parasympathetic innervation and hence there 
was no satistically significant vasodilation associated with transdermal nicotine at the 
finger.  
Nitroglycerin is a known vasodilator which works via a different mechanism from 
nicotine.  It is able to produce vasodilation without activating the parasympathetic 
nervous system.  In 1977 Murad discovered that nitric oxide release caused by nitrates 
relaxes smooth muscle cells. In addition, in 1986 Ignarro proposed that endothelium 
derived relaxing factor (EDRF) is identical to NO.  These Nobel prize winners 
established the involvement of endothelium in the coordination of numerous vasoactive 

















ANALYSIS OF RHYTHMIC SIGNALS OF THE AUTONOMIC NERVOUS 
SYSTEM 
 
In other to maintain the delicate homeostasis required for sustaining life, the body 
must be able to respond appropriately to both external and internal stimuli. These 
responses are carried out by the autonomic nervous system through dynamic interactions 
of rhythmically discharging neuronal networks. This physiological control system 
consists of both the sympathetic and parasympathetic branches which are each 
characterized by rhythmic activity. These biologic rhythms include slow and fast 
components and the cycle times can be measured and characterized using various 
mathematical manipulations to extract the wealth of information hidden within. Each 
branch of the autonomic nervous system oscillates within a specific range. The existence 
of a rhythm in the autonomic nervous system is important in that it allows the 
coordination of the numerous components of the system and it also gives us the ability to 
predict future events.  Moreover, each component oscillates at a particular frequency and 
hence this allows characterization of the response.  
Sympathetic activity is associated with the low frequency range 0.05- 0.11 Hz 
while parasympathetic activity is associated with intermediate range (0.11-0.19 Hz) and 
high range (0.2-0.3Hz) oscillations, with the later associated with respiration.  Hence, a 





analyzing the data in both the time and frequency domains as we looked for changes in 
amplitude and frequency as well as measuring the changes in mean blood flow.  
Chartview, the software used to acquire the data has built in functions for this analysis.  
Hence spectral analysis allows us to determine whether the response was predominantly 
parasympathetic or sympathetic. This involved converting the data from the time domain 
into a frequency domain which allowed us to measure the magnitude of the change in 
power at a given frequency.   
It is very common for information to be encoded in the sinusoids that form a 
signal. This is true of naturally occurring signals, as well as those that have been created 
by humans. Many things oscillate in our universe. The shape of the time domain 
waveform is not important in these signals; the key information is in the frequency, phase 
and amplitude of the component sinusoids.  A fourier transform can be utilized to extract 
these data allowing us to look more closely at the frequencies. Hence spectral analysis 
allows us to determine whether the response was predominantly parasympathetic or 
sympathetic. 
In our case this was used to study the amplitude, frequency and the power of the 
signals.  It is clear that there is oscillatory activity in the forehead nicotine with an 













ORGANIZATION OF ANS: REGIONAL DIFFERENCES IN INNERVATION 
 
 The differences in responses to transdermal nicotine and nitroglycerin support the 
hypothesis that there are differences in the innervations to the finger and the forehead. 
Moreover, the different degrees of vasodilation in response to nitroglycerin in the 
forehead and finger suggest that the differences also exist in the vasculature itself.  The 
forehead produced a much larger increase in blood flow compared with the finger for 
both nicotine and nitroglycerin.  
 Given the mechanism of action of nicotine, it is not surprising that transdermal 
nicotine failed to produce a significant change in blood flow as detected by laser doppler 
when applied to the finger.  This is due to the fact that the autonomic innervation of the 
vasculature in the limb skeletal muscles is primarily sympathetic. In addition, this is 
mostly vasoconstrictive and noradrenergic.   As mentioned earlier, nicotine binds to 
nicotinic receptors at the pre-to post ganglionic junctions. In the case of the sympathetic 
system to the upper limb, these synapses are found in the middle to caudal thoracic spinal 
segments  and possibly from the lower part of the cervical portion of the sympathetic 
ganglionic cord. Hence, the low dose of transdermal nicotine applied in this study was 
unable to access them and activate the sympathetic response. Despite this theory, 
Nicotine was associated with an increase in blood flow in 2/10 subjects which may 





 It is well known that there is no parasympathetic innervation to the upper and 
lower extremities. The primary role of the parasympathetic nervous system is internal 
maintenance, digestion and excretion. Therefore, there were no parasympathetic synapses 
near the end organ (i.e microvasculature) as was the case in the forehead for the 
transdermal nicotine to activate. 
 The forehead microvasculature is richly innervated by both sympathetic and 
parasympathetic fibers.  These include the cranial parasympathetic, superior cervical 

























NICOTINE AS A MEANS TO ASSESS THE  MICROVASCULAR FUNCTION 
 
The role of transdermal nicotine patches in smoking cessation is well established 
and hence these patches are already widely used for that purpose. However, as elucidated 
in this study, transdermal nicotine patches may well be an ideal tool for testing and 
assessing the function of the microvasculature. In order for transdermal nicotine to 
produce a vasodilatory response, the parasympathetic fibers innervating the 
microvasculature must be intact. Hence transdermal nicotine assesses both the 
innervation ( i.e the post ganglionic pathway) as well as the vessel itself. Many diseases 
affect the microvasculature such as diabetes, hypertension and preeclampsia.  
This test would be valuable in assessing diabetic neuropathy. Current diabetic 
clinical guidelines recommend annual screening for neuropathy but the literature is 
unable to provide specific support for a particular screening test due to a lack of evidence 
for its validity in the medical literature. In fact, the optimal method for screening for 
neuropathy has been controversial and is based on expert opinion rather than clinical 
evidence. [8]  The development of diabetic neuropathy is an insidious and progressive 
process which is not well correlated to the development of symptoms. Diabetic 
neuropathy leads to significant morbidity and mortality as it leads to painful paresthesias, 
sensory ataxia, ulceration and amputation. Screening and early identification allows an 





such as early foot care before the effects start to unfold. The current screening modalities 
in use include mainly the Semmes-Weinstein 5.07/10g monofilament, vibration testing 
with a 128 Hz tuning fork and superficial pain sensation testing. [8] 
The main advantage of using laser Doppler flowmetry in conjunction with 
transdermal nicotine patch is that it would be non invasive, able  to detect dysfunction at 
an earlier stage, would be user independent and patient independent in the sense that the 
patient will not have to subjectively qualify the decreases in sensation. Like any other 
quantifiable measurement such as blood pressure, we would be able to better stratify risks 
through studies and make recommendations based on those values with the clinical 
picture in mind. Clinical trial evidence for the efficacy of screening strategies 
demonstrated reduced outcomes of amputation and ulceration and, consequently, 





















NITROGLYCERIN AS A MEANS TO ASSESS THE ENDOTHELIUM 
 
 The endothelial cells release a wide number of molecules that regulate 
homeostasis, vasomotor activity, hemostasis and inflammation. Nitric oxide is one of 
these molecules and has numerous effects. Nitric oxide has vasodilatory, anti-
inflammatory, antithrombotic effects, antioxidant, antiapoptotic and antithrombotic 
effects.  Hence endothelial dysfunction has the potential to affect many different 
regulation pathways. Endothelial dysfunction is important in a number of disease states.  
This dysfunction leads to a pro-inflammatory and pro-thrombotic state that is thought to 
play a major role in the development of atherosclerosis and its accompanying clinical 
complications. Moreover, it is also thought to be a predictor of an increased rate of 
adverse cardiovascular events.   
The endothelium is often evaluated in terms of its vasodilatory function. Several 
methods are available for assessing endothelial function by measuring endothelial 
dependent vasodilation. Vasodilation can be induced by the direct infusion of a 
vasodilator such as acetylcholine or non invasively by the increase in blood flow velocity 
caused by post occlusive hyperemia.  Using a transdermal patch with a Laser Doppler 
probe provides a quick, non invasive way of assessing the endothelial function which is 
also quantifiable.  It is clear that nitroglycerin produced in measurable response 
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